Sanofi Trades In Phase III TroVax For Early-Stage Ophthalmology Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi Aventis returns cancer vaccine TroVax to Oxford BioMedica and signs option deal for four gene-based ocular products.
You may also be interested in...
Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.
Oxford BioMedica Combines With Mayo Clinic On Gene Therapy For Glaucoma
Oxford BioMedica and U.S. researchers at the Mayo Clinic are to use the company's lentivirus vector to deliver two prostaglandin-related genes into the front of the eye to alleviate glaucoma.
Sanofi Creates Ophtho Division through Earn-Out Acquisition of Fovea
By buying its Paris-based neighbor, Sanofi-Aventis creates an ophthalmology division and a chance to license more.